A patient with Graves’ disease showing only psychiatric symptoms and negativity for both TSH receptor autoantibody and thyroid stimulating antibody
© Hamasaki et al.; licensee BioMed Central Ltd. 2012
Received: 26 October 2012
Accepted: 27 November 2012
Published: 3 December 2012
Both thyroid stimulating hormone (TSH) and thyroid stimulating antibody (TSAb) negative Graves’s disease (GD) is extremely rare. Here we present such a patient.
The patient was a 76-year-old woman who was diagnosed as having schizophrenia forty years ago. She did not show characteristic symptoms for hyperthyroidism, such as swelling of thyroid, exophthalmos, tachycardia and tremor, however, she showed only psychomotor agitation. Serum free triiodothyronine and free thyroxine levels were elevated and TSH level was suppressed, suggesting the existence of hyperthyroidism. However, both the first generation TSH receptor autoantibody (TRAb1) and the thyroid stimulating autoantibody (TSAb) were negative. Slightly increased blood flow and swelling was detected by thyroid echography. Thyroid scintigraphy demonstrated diffuse and remarkably elevated uptake of 123I uptake. Finally, we diagnosed her as having GD. She was treated by using methimazole, and hyperthyroidism and her psychiatric symptoms were promptly ameliorated.
We experienced a patient with GD who did not show characteristic symptoms except for psychiatric symptoms, and also showed negativity for both TRAb1 and TSAb. Thyroid autoantibody-negative GD is extremely rare. Thyroid scintigraphy was useful to diagnose such a patient.
KeywordsDelusion Hyperthyroidism Scintigraphy Thyroid stimulating autoantibody TSH receptor autoantibody
Graves’ disease (GD) is induced by autoimmunity for the thyroid gland, and thyroid stimulating autoantibodies may be the main pathological cause of GD. We usually measure thyroid stimulating hormone (TSH) receptor autoantibodies for diagnosis for GD in medical practices. In fact, TSH receptor autoantibodies are detectable in over 90% of patients with GD .
Here we present a patient with GD showing the absence of characteristic symptoms and negativity for both the first generation TSH receptor autoantibody (TRAb1) and thyroid stimulating antibody (TSAb).
A 76–year-old woman was admitted to the Department of Psychiatry in our hospital because she denied medications and suffered from irritability and delusion. She had no complaints of somatic symptoms. Her thyroid function was normal at least four months before the admission, however, laboratory data on the admission revealed hyperthyroidism. She was pointed out to have thyroid disease thirty years ago, however, she was not diagnosed definitively at that time, and also did not take any medicine. She had also type 2 diabetes, hypertension, dyslipidemia, hyperuricemia and schizophrenia. The members of her family did not have thyroid disorders. She has been taking clonazepam (0.5 mg/day), trazodone (50 mg/day), nitrazepam (5 mg/day), 0.1% aripiprazole (6 ml/day), propranolol (30 mg/day) and telmisartan (40 mg/day), for the treatment for hypertension, psychiatric symptoms and schizophrenia.
Hyperthyroidism is a condition where the thyroid gland abnormally produces too much thyroid hormones. The most common cause is GD [2, 3], and which is developed by the autoimmune stimulation of the thyroid gland . Standardized diagnostic criteria for GD has not been globally established, and we usually diagnose this disease by clinical manifestations, laboratory data and imaging studies . Clinical symptoms and signs include body weight loss, tremor, irritability, tachycardia, goiter, exophthalmos. Our patient had no specific somatic symptom of GD. Adrenergic hyperactivity induces psychiatric symptoms in hyperthyroidism, however. GD patients presenting only delusion like our patient are uncommon [5, 6].
Paunkovic analyzed 255 patients diagnosed as having GD based on clinical manifestations and laboratory findings (free T4 and TSH). They excluded TRAb positive patients and the rest of the patients who had hyperthyroidism were re-tested with thyroid scintigraphy and serum levels of another TRAb. These results showed that TRAb were detectable in 98.7% of patients with GD. They stated TRAb negative GD was extremely rare, but there were methodological limitations in the assessment of only TRAb for the valid diagnosis of GD .
Our case showed no evident clinical manifestations except for psychomotor agitation which was considered to be induced by schizophrenia, and also showed negativity for both TRAb1 and TSAb. We observed a very weak positivity of TRAb2 before we started treatment. However, TRAb or TSAb have been reported to emerge in about 10% of patients with painless thyroiditis [8, 9], therefore, we cannot make a definite differential diagnosis between GD and painless thyroiditis even if one of the thyroid autoantibodies is very weakly positive. The recommended cut-off value of TRAb2 used to be 2.0 IU/L and the sensitivity is 93.9% with 100% specificity . It may be evident that the autoimmune stimulation of the thyroid gland is the cause of hyperthyroidism in our patient because serum levels of thyroid autoantibodies (TRAb1, TRAb2 and TSAb) were significantly decreased after starting treatment (Figure 2). We believe that present case is very rare. Our study also suggested that thyroid scintigraphy is very useful to diagnose GD patients with the absence of characteristic symptoms, TRAb and TSAb.
Thyroid autoantibody-negative GD is extremely rare. We experienced a patient with GD who did not show characteristic symptoms except for psychiatric symptoms, and also showed negativity for both TRAb1 and TSAb. Thyroid scintigraphy was useful to diagnose such a patient.
Written informed consent was obtained from the patient's relatives for publication of this case report. A copy of the written consent is available for review by the Eitor-in-Chief of this jounal.
- Zöphel K, Roggenbuck D, Schott M: Clinical review about TRAb assay's history. Autoimmun Rev 2010, 9: 695–700. 10.1016/j.autrev.2010.05.021PubMedView Article
- Weetamn AP: Graves’ disease. N Engl J Med 2000, 343: 1236–1248. 10.1056/NEJM200010263431707View Article
- Cooper DS: Hyperthyroidism. Lancet 2003, 362: 459–468. 10.1016/S0140-6736(03)14073-1PubMedView Article
- Brent GA: Graves’ Disease. N Engl J Med 2008, 358: 2594–2605. 10.1056/NEJMcp0801880PubMedView Article
- Bunevičius R, Prang AJ Jr: Thyroid disease and mental disorders: cause and effect or only comorbidity? Curr Opin Psychiatry 2010, 23: 363–368. 10.1097/YCO.0b013e3283387b50PubMedView Article
- Ogah OS, Timeyin AO, Kayode OA, Otukoya AS, Akinyemi RO, Adeyemi FI: Graves’ disease presenting as paranoid schizophrenia in a Nigerian woman: a case report. Cases Journal 2009, 2: 6708. 10.4076/1757-1626-2-6708PubMed CentralPubMedView Article
- Paunkovic J, Paunkovic N: Does autoantibody-negative Graves’ disease Exist ? A second evaluation of the clinical diagnosis. Horm Metab Res 2006, 38: 53–56. 10.1055/s-2006-924979PubMedView Article
- Iitaka M, Morgenthaler NG, Momotani N, Nagata A, Ishikawa N, Ito K, Katayama S, Ito K: Stimulation of thyroid-stimulating hormone (TSH) receptor antibody production following painless thyroiditis. Clin Endocrinol 2004, 60: 49–53. 10.1111/j.1365-2265.2004.01939.xView Article
- Takasu N, Kamijo K, Sato Y, Yoshimura H, Nagata A, Ochi Y: Sensitive Thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves’ disease. Clin Exp Pharmacol Physiol 2004, 31: 3124–3319.View Article
- Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA, Seissler J: Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. Horm Metab Res 2000, 32: 429–435. 10.1055/s-2007-978666PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.